FDA Grants Brigatinib Priority Review for ALK-Positive NSCLC
The FDA has has granted a priority review to a new drug application (NDA) for brigatinib for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) who are resistant to prior crizotinib (Xalkori), according to a statement from the drug's developer, ...Leggi tutto
